Definition/General
Introduction:
Adult T-Cell Leukemia/Lymphoma (ATL) is an aggressive mature T-cell neoplasm caused by Human T-lymphotropic Virus Type 1 (HTLV-1)
It represents the first well-documented viral etiology of human lymphoma
ATL develops after a long latency period (20-60 years) following HTLV-1 infection
The disease shows distinct geographic distribution correlating with HTLV-1 endemic areas.
Origin:
Arises from HTLV-1 infected mature T-lymphocytes with helper phenotype (CD4+)
The virus integrates into host T-cell genome and remains dormant for decades
Viral Tax protein disrupts cell cycle regulation and promotes genomic instability
Clonal evolution leads to malignant transformation
The process requires multiple genetic hits beyond viral infection.
Classification:
Shimoyama classification recognizes four clinical subtypes: Acute ATL (most aggressive - 60% cases)
Lymphomatous ATL (nodal disease - 20% cases)
Chronic ATL (indolent course - 15% cases)
Smoldering ATL (asymptomatic - 5% cases)
Each subtype has distinct clinical features and prognosis.
Epidemiology:
Endemic in southwestern Japan, Caribbean, parts of Africa, South America
Rare in India except certain tribal populations
Lifetime risk of ATL in HTLV-1 carriers is 2-5%
Male predominance (1.5:1 ratio)
Peak incidence in 5th-6th decades
Associated with vertical transmission of HTLV-1 (mother to child).
Clinical Features
Presentation:
Acute ATL: high WBC count, hypercalcemia, skin lesions, organ infiltration
Lymphomatous ATL: lymphadenopathy, normal WBC, no hypercalcemia
Chronic ATL: lymphocytosis, skin lesions, mild organomegaly
Smoldering ATL: minimal symptoms, <5% abnormal lymphocytes
Hypercalcemia characteristic of acute subtype (70% cases).
Symptoms:
Skin lesions (50-70% cases): papules, nodules, plaques, erythroderma
Hypercalcemia symptoms: confusion, polyuria, kidney stones, bone pain
B-symptoms: fever, night sweats, weight loss
Opportunistic infections due to immunosuppression
GI symptoms: diarrhea, abdominal pain
Neurologic symptoms (CNS involvement).
Risk Factors:
HTLV-1 seropositivity (essential risk factor)
Endemic area residence or origin
Mother-to-child transmission (breastfeeding, birth)
Advanced age (>40 years in carriers)
Male gender
Prolonged HTLV-1 infection (>20 years)
Immunosuppression may accelerate progression.
Screening:
HTLV-1 serology essential for diagnosis
Screen high-risk populations in endemic areas
Family screening if index case identified
Blood donor screening in endemic regions
Annual monitoring of HTLV-1 carriers for lymphocytosis
Flow cytometry for abnormal T-cell populations.
Master ATL Pathology with RxDx
Access 100+ pathology videos and expert guidance with the RxDx app
Gross Description
Appearance:
Lymphadenopathy variable depending on subtype (prominent in lymphomatous ATL)
Splenomegaly common in acute and chronic subtypes
Hepatomegaly in 50-60% cases
Skin lesions: variable from subtle erythema to tumor nodules
Bone marrow infiltration in leukemic forms.
Characteristics:
Lymph nodes show complete architectural effacement in lymphomatous type
Tan-white cut surface without necrosis
Spleen shows red and white pulp infiltration
Skin lesions show dermal infiltration with epidermotropism
Multiple organ infiltration in acute ATL.
Size Location:
Lymphadenopathy: generalized distribution in lymphomatous ATL
Mediastinal involvement less common than in T-lymphoblastic lymphoma
Spleen: moderate enlargement (2-5 times normal)
Skin lesions: widespread distribution possible
CNS involvement in 10-15% cases.
Multifocality:
Systemic disease with multi-organ involvement potential
Leukemic presentation in acute and chronic subtypes
Nodal disease predominant in lymphomatous subtype
Extranodal sites: skin, GI tract, lungs, CNS, bone
Opportunistic infections due to immunosuppression.
Microscopic Description
Histological Features:
ATL cells show pleomorphic morphology with size variation
Flower cells are pathognomonic (multilobated nuclei resembling flower petals)
Medium to large lymphocytes with irregular nuclear contours
Hyperchromasia and prominent nucleoli
Moderate to abundant basophilic cytoplasm
High mitotic activity in aggressive subtypes.
Cellular Characteristics:
Flower cells: characteristic multilobated, convoluted nuclei
Nuclear pleomorphism with size variation
Coarse chromatin pattern
Prominent nucleoli (1-3 per cell)
Cytoplasm moderately basophilic with occasional vacuoles
Giant cells may be present (multinucleated forms).
Architectural Patterns:
Lymph nodes show diffuse infiltration with architectural effacement
Cohesive growth pattern unlike some other T-cell lymphomas
Skin shows dermal infiltration with epidermotropism
Angioinvasion may be present
Bone marrow shows interstitial and focal infiltration.
Grading Criteria:
No formal grading system
Classification based on clinical subtypes (acute, lymphomatous, chronic, smoldering)
Proliferation index varies by subtype (high in acute, low in smoldering)
Degree of pleomorphism correlates with aggressiveness
Transformation from indolent to aggressive subtypes possible.
Immunohistochemistry
Positive Markers:
CD2, CD3, CD5 (pan-T-cell markers positive)
CD4+ (helper T-cell phenotype in >90% cases)
CD25 (IL-2 receptor, strongly positive)
CD30 positive in large cell variants
Foxp3 may be positive (regulatory T-cell features)
CCR4 positive (important therapeutic target).
Negative Markers:
CD8 usually negative (CD4+ phenotype predominant)
CD7 frequently lost (aberrant phenotype)
TdT negative (mature T-cell phenotype)
CD1a negative
ALK negative (unlike ALK+ ALCL)
EBV/EBER negative.
Diagnostic Utility:
Characteristic immunophenotype: CD3+, CD4+, CD25+, CD7-, CCR4+
Loss of CD7 is characteristic aberrancy
Strong CD25 expression correlates with HTLV-1 Tax protein activity
CCR4 positivity enables targeted therapy
Foxp3 expression suggests regulatory T-cell origin.
Molecular Subtypes:
All ATL subtypes share similar immunophenotype
CD30 expression more common in large cell/anaplastic variants
Cytotoxic markers (TIA-1, granzyme) usually negative
TCR expression may be aberrant
PD-1 expression variable (may predict checkpoint inhibitor response).
Molecular/Genetic
Genetic Mutations:
HTLV-1 proviral DNA integration (diagnostic marker)
TP53 mutations in 30-40% cases (associated with progression)
TCR gene rearrangements clonal
CDKN2A deletions common
PLCG1 mutations in 30% cases
CCR4 and CCR7 mutations in some cases.
Molecular Markers:
HTLV-1 Tax protein disrupts multiple cellular pathways
Clonal HTLV-1 integration sites prove viral etiology
High viral load in acute subtypes
NF-κB pathway activation (Tax-mediated)
Genomic instability with complex karyotypes
Telomerase activation.
Prognostic Significance:
Clinical subtype most important prognostic factor
Acute ATL: median survival 6-10 months
Lymphomatous ATL: median survival 10-12 months
Chronic ATL: years of survival possible
Smoldering ATL: may remain stable for years
Hypercalcemia indicates poor prognosis.
Therapeutic Targets:
CCR4 targeted by mogamulizumab (anti-CCR4 antibody)
CD25 targeted by daclizumab
Proteasome inhibitors effective against NF-κB pathway
HDAC inhibitors show activity
Allogeneic stem cell transplant for eligible patients
Zidovudine + interferon-α for chronic subtypes.
Differential Diagnosis
Similar Entities:
T-cell Prolymphocytic Leukemia (TCL1+, aggressive)
Sézary Syndrome (cutaneous, cerebriform cells)
Peripheral T-cell Lymphoma, NOS
Anaplastic Large Cell Lymphoma (ALK+/-)
Cutaneous T-cell Lymphoma (mycosis fungoides)
Large Granular Lymphocytic Leukemia.
Distinguishing Features:
ATL: HTLV-1+, flower cells, CD25+, geographic clustering
T-PLL: TCL1+, HTLV-1-, different morphology
Sézary: HTLV-1-, cerebriform nuclei, cutaneous
PTCL: HTLV-1-, different immunophenotype
ALCL: ALK+/-, CD30+, different morphology
CTCL: HTLV-1-, cutaneous presentation.
Diagnostic Challenges:
HTLV-1 serology essential for diagnosis (false negatives rare)
Flower cells may be subtle in some cases
Distinguishing chronic ATL from reactive HTLV-1 carriership
Smoldering ATL versus normal variant lymphocytes
Secondary infections may complicate morphology.
Rare Variants:
Primary cutaneous ATL: skin-limited disease (rare)
CNS ATL: primary central nervous system involvement
Anaplastic variant: large cell morphology, CD30+
Pleomorphic variant: marked cellular pleomorphism
Hodgkin-like variant: Reed-Sternberg-like cells.
Sample Pathology Report
Template Format
Sample Pathology Report
Complete Report: This is an example of how the final pathology report should be structured for this condition.
Specimen Information
Peripheral blood, lymph node biopsy, skin biopsy, bone marrow (as applicable)
HTLV-1 Serology
HTLV-1 antibodies: Positive [confirmed by Western blot]
Cell Morphology
Pleomorphic T-lymphocytes with flower cells ([present/absent])
Peripheral Blood Findings
WBC: [count]/μL with [X]% abnormal lymphocytes
Flow Cytometry/Immunohistochemistry
CD3+, CD4+, CD25+, CD7-, CCR4+ T-cell population
Clinical Subtype
[Acute/Lymphomatous/Chronic/Smoldering] ATL based on clinical criteria
Key Laboratory Findings
Hypercalcemia: [present/absent], LDH: [level]
Staging
Stage [I-IV] with [organ involvement details]
Molecular Studies
HTLV-1 proviral DNA: [detected], TCR gene rearrangement: [clonal]
Final Diagnosis
Adult T-Cell Leukemia/Lymphoma, [clinical subtype], HTLV-1 positive